Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3M2BX)

Drug Name

VLX-1005 Drug Info

Synonyms

ML355; 1532593-30-8; ML355 free base; ML-355; VLX-1005; N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide; JKU4XCC48Y; CHEMBL3113165; ML 355; N-(1,3-benzothiazol-2-yl)-4-{[(2-hydroxy-3-methoxyphenyl)methyl]amino}benzene-1-sulfonamide; N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide; Benzenesulfonamide, N-2-benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)-; N-2-Benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)benzenesulfonamide; N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-benzenesulfonamide; NCGC00263773-03; N-2-Benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide; ZR5; UNII-JKU4XCC48Y; GTPL8752; SCHEMBL16646023; VLX1005; CHEBI:195557; BCP28954; EX-A1987; VLX 1005; BDBM50447175; s6557; AKOS030526578; CS-3351; NCGC00263773-01; NCGC00263773-18; AC-36858; BS-15552; HY-12341; A908037; Q27087172; N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonamide; N-(Benzo[d]thiazol-2-yl)-4-(2-hydroxy-3-methoxybenzylamino)benzenesulfonamide; ML-355; ML-355;N-(Benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Heparin-induced thrombocytopenia	3B64.12	Phase 2	[1]

Cross-matching ID

PubChem CID: 70701426
TTD Drug ID: DM3M2BX

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)	TTQ4QQH	LX12B_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05785819) A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Veralox Therapeutics